Veeva Systems (VEEV) AI Stock Analysis

• Market Cap: $47.58B
• Dividend Yield: N/A
• Average Volume (3M): 1.41M
• Price to Earnings (P/E): 59.6
• Beta (1Y): 0.99
• Revenue Growth: 15.33%
• EPS Growth: 30.51%
• Country: US
• Employees: 7,291
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.99
• Shares Outstanding: 163,908,020
• 10 Day Avg. Volume: 1,185,861
• 30 Day Avg. Volume: 1,412,696
• PEG Ratio: 1.52
• Price to Book (P/B): 6.47
• Price to Sales (P/S): 13.75
• P/FCF Ratio: 35.31
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 13.93
• Enterprise Value/Gross Profit: 18.42
• Enterprise Value/Ebitda: 49.26
• 1Y Price Target: $318.79
• Price Target Upside: 9.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 23

• Rating: 77 Outperform
• Price Target: $317.00 ▲(9.21% Upside)

Veeva Systems' overall stock score is driven by its robust financial performance and positive earnings call, which highlight strong profitability and strategic advancements. However, the high P/E ratio suggests potential overvaluation, and mixed technical indicators indicate no clear trend, tempering the overall score.

Positive Factors

Strong Financial Health

Veeva's robust financial health, characterized by high profitability and strong cash flow, provides a stable foundation for sustained growth and strategic investments.

Resolution of IQVIA Lawsuit

Resolving the IQVIA lawsuit allows Veeva to integrate IQVIA data, enhancing product offerings and opening new collaboration opportunities, strengthening its market position.

AI Development

Advancements in AI development position Veeva to expand its market size and improve operational efficiency, driving long-term growth and competitive advantage.

Negative Factors

Challenges with Product Adoption

Resistance to new product adoption can hinder growth in certain segments, requiring strategic adjustments to overcome market reluctance and drive uptake.

Flat Growth in Commercial Cloud

Flat growth in commercial cloud subscriptions suggests potential saturation or competitive pressures, necessitating innovation to reignite growth in this segment.

Market Resistance

Market resistance to new products like Compass Prescriber indicates potential challenges in achieving anticipated growth, impacting revenue projections.

Veeva Systems Business Overview & Revenue Model

Company Description

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM MyInsights, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva OpenData, Veeva Link, Veeva Network, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Patients; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

How the Company Makes Money

Veeva Systems generates revenue primarily through subscription-based services. The company offers its software solutions via a cloud model, allowing customers to pay for access on a recurring basis. Key revenue streams include subscriptions to its various applications, such as Veeva Vault, Veeva CRM, and Veeva Network, which cater to different aspects of life sciences operations, including clinical trials, regulatory submissions, and commercial sales. Veeva also provides professional services to assist clients in implementing and optimizing its software. Significant partnerships with major pharmaceutical companies and ongoing investments in product development further contribute to its earnings, as does the growing demand for cloud-based solutions in the life sciences sector.

Veeva Systems Financial Statement Overview

Summary

Veeva Systems presents a robust financial profile with strong profitability, a solid balance sheet, and impressive cash flow metrics. The company demonstrates consistent revenue growth and efficient operations, supported by low leverage and high equity. Overall, Veeva Systems is well-positioned for continued financial success in the healthcare information services industry.

Income Statement

Veeva Systems demonstrates strong profitability with a TTM gross profit margin of 75.59% and a net profit margin of 27.29%. Revenue growth is steady at 3.95% TTM, indicating consistent expansion. EBIT and EBITDA margins are robust at 29.27% and 29.94% respectively, reflecting efficient operations. Overall, the company shows solid financial health with a positive growth trajectory.

Balance Sheet

The balance sheet is strong with a low debt-to-equity ratio of 0.0129, indicating minimal leverage and financial risk. Return on equity is healthy at 13.40% TTM, showcasing effective use of equity capital. The equity ratio is solid, reflecting a stable financial structure. Veeva Systems maintains a strong balance sheet with low debt and high equity.

Cash Flow

Cash flow metrics are impressive with a free cash flow growth rate of 12.48% TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.08, and the free cash flow to net income ratio is 0.99, both suggesting efficient cash flow management. Veeva Systems exhibits strong cash flow performance, supporting its operational and financial stability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.97B	2.75B	2.36B	2.16B	1.85B	1.47B
Gross Profit	2.24B	2.05B	1.69B	1.55B	1.35B	1.06B
EBITDA	839.23M	730.82M	461.96M	488.21M	532.94M	407.25M
Net Income	809.93M	714.14M	525.71M	487.71M	427.39M	380.00M
Balance Sheet
Total Assets	8.00B	7.34B	5.91B	4.80B	3.82B	3.05B
Cash, Cash Equivalents and Short-Term Investments	6.40B	5.15B	4.03B	3.10B	2.38B	1.66B
Total Debt	85.45M	75.78M	55.77M	60.98M	54.59M	63.12M
Total Liabilities	1.36B	1.51B	1.27B	1.09B	904.83M	779.75M
Stockholders Equity	6.64B	5.83B	4.64B	3.72B	2.91B	2.27B
Cash Flow
Free Cash Flow	1.33B	1.07B	885.14M	766.96M	750.25M	542.56M
Operating Cash Flow	1.35B	1.09B	911.34M	780.47M	764.46M	551.25M
Investing Cash Flow	-755.30M	-700.14M	-1.08B	-1.01B	-346.15M	-333.63M
Financing Cash Flow	169.84M	26.11M	-16.19M	-19.38M	-4.14M	33.82M

Veeva Systems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 290.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VEEV, the sentiment is Positive. The current price of 290.27 is above the 20-day moving average (MA) of 276.94, above the 50-day MA of 280.94, and above the 200-day MA of 250.52, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 61.52 is Neutral, neither overbought nor oversold. The STOCH value of 73.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VEEV.

Veeva Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DOCS	80 Outperform	$13.94B	63.87	22.93%	―	19.45%	46.46%
HQY	79 Outperform	$8.32B	58.44	6.79%	―	15.45%	37.72%
VEEV	77 Outperform	$47.58B	59.55	13.70%	―	15.33%	30.51%
GEHC	77 Outperform	$33.08B	14.83	23.07%	0.19%	2.30%	41.46%
BTSG	76 Outperform	$4.85B	92.66	3.76%	―	20.60%	―
TEM	59 Neutral	$13.63B	-66.27	-64.52%	―	59.84%	76.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%